bullish
Newron Pharmaceuticals - Evenamide trial progressing well
SUMMARY
Newron has reported excellent, fast recruitment for the Phase II study of its novel schizophrenia drug, Evenamide, due to report in Q121. Newron notes that Phase III trials could start in Q221. It is progressing possible partnering deals on Evenamide. Discussions with Zambon on a Xadago dyskinesia study are moving forward. Newron had €39m cash at end June 2020 with cash well into 2022. Xadago royalties were up 14% at €2.5m vs €2.2m in H119. Our indicative value remains at CHF121m.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Edison Investment Research
Leading International Investment Research
Price Chart(Sign Up to Access)
- Newron Pharmaceuticals - Evenamide trial progressing well22 Sep 2020
x